Lupin

News

Zydus follows Lupin with Myrbetriq settlement deal

Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.

News

Lupin settles Myrbetriq patent spat with Astellas for $90m

Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.

News

Astellas’ generic Myrbetriq defence knocked back again

Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics.

Zydus follows Lupin with Myrbetriq settlement deal

Lupin settles Myrbetriq patent spat with Astellas for $90m

Astellas’ generic Myrbetriq defence knocked back again

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks